Home / PDA Letter / Full Article

Another Perspective on rFC

by Allen Burgenson, Lonza

Published On Aug 5, 2019

I have noticed that a few articles have been published recently questioning the use of recombinant Factor C (rFC) assays to detect endotoxin contamination in parenterally administered pharmaceuticals or implanted medical devices [Editor’s Note: See list of previous rFC-related articles at end of article.]. There seems to be some confusion regarding the history of the development of the limulus amebocyte assay (LAL) assay, the development of the rFC assay and its regulatory status.

The contents of "Another Perspective on rFC" are available to PDA members. Please sign up or log in to read the full article.